D
David Beidler
Researcher at Pfizer
Publications - 19
Citations - 1228
David Beidler is an academic researcher from Pfizer. The author has contributed to research in topics: Fatty acid amide hydrolase & Anandamide. The author has an hindex of 13, co-authored 19 publications receiving 1119 citations.
Papers
More filters
Journal ArticleDOI
Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Kay Ahn,Douglas S. Johnson,Mauro Mileni,David Beidler,Jonathan Z. Long,Michele K. McKinney,Eranthie Weerapana,Nalini Sadagopan,Marya Liimatta,Sarah E. Smith,Lazerwith Scott E,Cory Michael Stiff,Satwik Kamtekar,Keshab Bhattacharya,Yanhua Zhang,Stephen Swaney,Keri Van Becelaere,Raymond C. Stevens,Benjamin F. Cravatt +18 more
TL;DR: Mechanistic and structural studies confirm that PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile, and designate PF- 3845 as a valuable pharmacological tool for in vivo characterization of the endocannabinoid system.
Journal ArticleDOI
Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain
Kay Ahn,Sarah E. Smith,Marya Liimatta,David Beidler,Nalini Sadagopan,David T. Dudley,Tim Young,Paul Bryan Wren,Yanhua Zhang,Steven Swaney,Keri Van Becelaere,Jacqueline L. Blankman,Daniel K. K. Nomura,Shoba N. Bhattachar,Cory Michael Stiff,Tyzoon K. Nomanbhoy,Eranthie Weerapana,Douglas S. Johnson,Benjamin F. Cravatt +18 more
TL;DR: Based on its exceptional selectivity and in vivo efficacy, combined with long duration of action and optimal pharmacokinetic properties, PF-04457845 is a clinical candidate for the treatment of pain and other nervous system disorders.
Journal ArticleDOI
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
Douglas S. Johnson,Cory Michael Stiff,Lazerwith Scott E,Suzanne Ross Kesten,Lorraine Kathleen Fay,Mark Morris,David Beidler,Marya Liimatta,Sarah E. Smith,David T. Dudley,Nalini Sadagopan,Shobha N. Bhattachar,Stephen J. Kesten,Tyzoon K. Nomanbhoy,Benjamin F. Cravatt,Kay Ahn +15 more
TL;DR: Compound 23 has exquisite selectivity for FAAH relative to other members of the serine hydrolase superfamily as demonstrated by competitive activity-based protein profiling and is being evaluated in human clinical trials.
Journal ArticleDOI
Proinflammatory cytokines, IL-1β and TNF-α, induce expression of interleukin-34 mRNA via JNK- and p44/42 MAPK-NF-κB pathway but not p38 pathway in osteoblasts.
TL;DR: Results showed that proinflammatory cytokines, IL-1β and TNF-α, induced the expression of IL-34 mRNA via JNK and p44/42 MAPK but not p38 in human osteoblasts while p38, JNK, and p 44/42MAPK were not involved in the induction of M-CSF mRNA expression by these cytokines.
Journal ArticleDOI
Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood.
Hiroyuki Eda,Jian Zhang,Robert H. Keith,Marshall L. Michener,David Beidler,Joseph B. Monahan +5 more
TL;DR: MCP-1 is the most appropriate chemokine target for a Chemokine release assay to evaluate the potency of c-FMS kinase inhibitors and MCP- 1 release assay using HWB would be useful, relevant tool for translational pharmacology of c.FMS Kinase inhibitors.